Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology

Jaidyn Muhandiramge1,2 · John R. Zalcberg1,3 · G. J. van Londen4 · Erica T. Warner5 · Prudence R. Carr1 · Andrew Haydon3 · Suzanne G. Orchard1

Accepted: 14 June 2022 / Published online: 7 July 2022 © The Author(s) 2022

Abstract
Purpose of Review Cardiovascular disease is long-term complication of both cancer and anti-cancer treatment and can have significant ramifications for health-related quality of life and mortality. This narrative review explores the current evidence linking cardiovascular disease and cancer, as well as exploring strategies for the prevention and management of cardiovascular disease, and outlines future opportunities in the field of cardio-oncology.

Recent Findings Cancer confers risk for various cardiovascular diseases including heart failure, cardiomyopathy, arrhythmia, coronary heart disease, stroke, venous thromboembolism, and valvular heart disease. Cancer treatment, in particular agents such as platinum-based chemotherapy, anthracyclines, hormonal treatments, and thoracic radiotherapy, further increases risk. While cardiovascular disease can be identified early and effectively managed in cancer survivors, cardiovascular screening and management does not typically feature in routine long-term cancer care of adult cancer survivors.

Summary Cancer and cancer treatment can accelerate the development of cardiovascular disease. Further research into screening and management strategies for cardiovascular disease, along with evidence-based guidelines, is required to ensure adult cancer survivors receive appropriate long-term care.

Keywords Cancer · Cardiovascular disease · Myocardial infarction · Heart failure · Stroke · Aging

Introduction

Both cancer and aging are inextricably linked by a central mechanism: an accumulation of cellular damage over time resulting in progressive cellular dysfunction and ensuing deficits across various organ systems [1, 2]. Aging is therefore widely accepted to be a strong risk factor for cancer [3]. However, aging processes may also be accelerated as a result of cancer and cancer treatment [4•, 5]. The functional outcomes of aging, sometimes referred to as clinical manifestations of aging, include various deficits such as functional decline, frailty, cognitive impairment, and chronic disease [4•, 5]. One important clinical manifestation of aging not often linked with cancer is cardiovascular disease (CVD) [6], a common group of disorders that typically encompass cardiac disease, arterial disease, and cerebrovascular disease (i.e. stroke) [7]. Many of these aging outcomes, however, are relatively under-represented in research.

In 2018, the National Cancer Institute assembled a think tank titled “Measuring Aging and Identifying Aging
Phenotypes in Cancer Survivors” to explore the challenges that exist in measuring, and subsequently preventing accelerated aging in cancer survivors. The resulting report identified a need for further research surrounding the clinical manifestations of aging in this cohort [4••]. Of all the clinical manifestations of aging, CVF is one that can be identified early, effectively managed, and in many cases prevented [8]. In spite of this, CVF screening and management does not typically feature in routine long-term cancer care. The intersection of CVF and cancer, along with a newfound understanding of the importance of cardiac care to patients with cancer, has led to the development of a relatively new field: cardio-oncology.

This narrative review explores the current evidence surrounding the increased risk of CVF due to cancer, as well as strategies for its prevention and management, and outlines where future research in cardio-oncology might be directed. The search strategy for this review can be found in the Supplementary Material.

Impact of Cancer on Risk of Cardiovascular Disease

Several large-scale studies support a positive association between CVF risk and cancer across multiple cancer types. Some of the literature on this topic is outlined below, with a preference for landmark or recent studies, large sample sizes, systematic reviews or meta-analyses, adjustment for anticancer treatment, and comparison with cancer-free controls.

Two analyses by Zoller et al. [9••, 10••] using large cohorts provide some of the earlier evidence for this link. In the first analysis, Zoller et al. [10••] investigated 820,491 Swedish individuals with cancer and compared them with the entire cancer-free population of Sweden. They indicated that while coronary heart disease risk was highest in the 6 months immediately post-diagnosis (Standardized Incidence Ratio [SIR] 1.70, 95% CI 1.66–1.75) and did decrease over time, it nonetheless remained elevated even after 10 years following a cancer diagnosis (SIR 1.07, 95% CI 1.04–1.11) [10••]. Zoller et al.’s [9••] analysis of the same cohort demonstrated over double the risk of stroke during the first 6 months following a diagnosis of cancer (SIR 2.2, 95% CI 2.0–2.3), with the risk attenuating rapidly, but nonetheless remaining elevated for 10 years post-diagnosis (SIR 1.2, 95% CI 1.1–1.3). Notably, neither analysis had access to cardiovascular risk factor data (e.g. smoking, weight, diet) nor cancer treatment data and therefore could not adjust for these variables, although they did adjust for basic demographic factors such as age and gender, along with relevant comorbidities such as hypertension and diabetes. Both studies also used hospitalisation for coronary heart disease or stroke as events, thereby excluding more minor CVF events treated in an outpatient setting.

More recently, a UK-based study by Strongman et al. [11••] conducted a time-to-event analysis of 108,215 patients with cancer and demonstrated persistently increased risks of heart failure, cardiomyopathy, arrhythmia, coronary heart disease, stroke, and valvular heart disease following the diagnosis of various cancers. While the risk of some events such as venous thromboembolism reduced over time, others such as heart failure and cardiomyopathy continued to increase over a period of over 12 years [11••]. Schoormans et al.’s [12] 2018 analysis of 32,757 Dutch cancer survivors corroborated these findings, with survivors of prostate, lung, and tracheal cancer demonstrating an increased risk of incident CVF over a follow-up period of up to 13 years. Notably, CVF risk in the latter two cancer types remained statistically significant after adjusting for cancer treatment type and CVF risk factors [12]. Paterson et al. [13••] similarly demonstrated statistically significant increases in the risk of stroke (HR 1.44, 95% CI 1.41–1.47), heart failure (HR 1.62, 95% CI 1.59–1.65), and pulmonary embolism (HR 3.43, 95% CI 3.37–3.50) in patients with cancer. The risk was further increased in patients with genitourinary, gastrointestinal, thoracic, nervous system, and hematologic malignancies. The study had several methodological strengths including a large sample size ($n_{\text{total}} = 4,519,243; n_{\text{cancer}} = 224,016$), long follow-up time (11.8 years), and adjustment for 31 comorbidities including nine cardiovascular comorbidities [13••]. A recent 2021 meta-analysis confirmed increased stroke risk in an analysis of 10,479,530 cancer survivors across 21 cohort studies, demonstrating a relative risk of 1.66 (95% CI 1.35–2.04) when compared to cancer-free controls. A diagnosis of head and neck, blood, lung, pancreas, and stomach cancer in particular was associated with a consistently significant increase in risk [14••].

Mechanisms Driving Cancer-Related Cardiovascular Disease

A causal association between the diagnosis (and/or treatment) of a tumour itself and CVF may exist, with most theories implicating cancer-induced inflammation as the common link [15]. There is evidence to suggest that activation of certain oncogenes and inactivation of tumour-suppressor genes may produce pro-inflammatory molecules, creating an inflammatory micro-environment that underpins the subsequent development of CVF [16]. C-reactive protein is one acute phase reactant that can be raised as a result of this inflammatory response and can be used as a predictor of progressive disease in some cancer types [17]. An increased incidence of CVF seen in patients with metastatic disease may support this link [9••], given the association between
a greater total tumour volume and increased inflammation. However, it should be noted that patients with advanced disease are also more likely to receive greater amounts of treatment and may therefore be impacted by this rather than the cancer itself. Nevertheless, it is clear that tumours can promote the release of pro-inflammatory cytokines and atherosclerotic plaque formation [18, 19], both mechanisms that underly the development of heart disease [6]. Early evidence also exists supporting a link between clonal hematopoiesis, cancer, and CVD. Clonal hematopoiesis is a condition characterized by the proliferation of hematopoietic stem cells carrying certain somatic mutations, and is typically associated with an increased risk of hematologic malignancy [20]. More recently, clonal hematopoiesis has also been linked to CVD, likely as a result of inflammatory processes accelerating atherosclerosis and venous thrombosis [21]. In a nested case–control of 8255 individuals, Jaiswal et al. demonstrated a 1.9-fold increase in the risk of coronary heart disease in carriers of clonal hematopoiesis compared with non-carriers [22]. Clonal hematopoiesis may therefore represent a shared inflammation-mediated mechanism by which patients with cancer develop CVD.

Stroke in cancer survivors is a more complicated phenomenon and may relate to several factors including direct tumour effects (e.g. vascular invasion, cancer-associated inflammation, tumour emboli) and coagulopathy [23]. Coagulopathy appears to be the primary driving factor in cancer-related stroke and is in turn driven by various mechanisms including thrombocytosis, tumour-expressed procoagulants, inflammation, and disseminated intravascular coagulopathy [23]. As is the case for heart disease, evidence suggests that cancer aggressiveness may influence stroke risk [9, 24], again suggesting a link between tumour load and cancer-associated inflammation.

Anti-cancer treatment appears to have an additional direct impact on heart disease. Radiotherapy has been shown to substantially increase cardiovascular risk in patients with cancers requiring thoracic radiation such as breast cancer, lung cancer, and Hodgkin’s lymphoma [25–27]. Notably, this risk is proportional to the proximity of the tumour site receiving radiation to the heart and, therefore, the total cardiac radiation dose received [28]. As a result, there is little evidence to suggest irradiation of tumours distant to the thorax (e.g. pelvic irradiation for prostate cancer) can cause similar levels of cardiac damage. Several systemic therapies including cytotoxic chemotherapy (e.g. anthracyclines), hormonal therapy (e.g. selective oestrogen receptor modulators, aromatase inhibitors, LHRH agonists and antagonists, androgen receptor antagonists) [29], targeted therapy (e.g. trastuzumab, kinase inhibitors), and immunotherapy (e.g. ipilimumab) have also been linked to CVD [30, 31]. Hormone-based treatments in particular confer risk for various cardiovascular diseases including dyslipidaemia, hypertension, venous thromboembolism, stroke, arrhythmia, myocardial infarction, and heart failure. Notably, the effects of each individual agent vary significantly due to their heterogeneous mechanisms of action, and while some increase risk for certain cardiovascular diseases, others provide a protective benefit [29]. The literature similarly supports a link between cancer treatment and cerebrovascular disease. In a pooled meta-analysis of 12 studies, Huang et al. [32] reported that patients who had received radiotherapy (to any site) experienced stroke at over double the rate of patients with cancer who had not received radiotherapy. Similarly, chemotherapy has been reported to increase stroke risk through a number of mechanisms, including endothelial dysfunction and disruption of normal coagulation and haemostasis [33]. Some cytotoxic chemotherapeutic agents, particularly platinum-based compounds such as cisplatin, confer considerable risk for stroke [33]. The mechanism driving this is less clear but may involve the release of prothrombotic endothelial and platelet-derived microparticles seen following cisplatin infusion [34]. Conversely, targeted therapy with anti-angiogenic tyrosine kinase inhibitors has not been directly linked to stroke. Some agents such as sunitinib, however, are known to cause thrombocytopenia and hypertension (a class effect common to many of the tyrosine kinase inhibitors), providing a potential link to hemorrhagic stroke [35]. Allogeneic hematopoietic stem-cell transplantation may also contribute to late cardiovascular effects in patients with hematologic malignancy. Tichelli et al. [36] demonstrated increased risk of arterial events in patients who had undergone such transplantation, with this risk persisting for several decades post-transplantation. Many of the cardiac effects of anti-cancer treatments are thought to contribute to the longer term CVD risk seen in cancer survivors, with mediastinal radiation and cardiotoxic chemotherapeutic agents being the most commonly cited culprits [37]. Fig. 1 provides a summary of some of the treatment modalities commonly associated with CVD.

The indirect impact of cancer and cancer treatment on CVD risk should also be considered. Exercise intolerance and subsequent sedentarism is one such sequelae of cancer that is common in survivors and can predispose to CVD [38, 39]. Sedentarism is undoubtedly an important consideration in assessing cardiovascular risk, with a 2016 American Heart Association review suggesting a link between sedentary behaviour and not only CVD risk, but also cardiovascular morbidity and mortality [39]. Sedentarism and a lack of cardiorespiratory fitness can be driven by several cancer-related mechanisms including inactivity secondary to cancer or treatment-related symptoms such as fatigue, pain, or physical limitations [40]. Cancer treatment can have an even more damaging effect on exercise tolerance, particularly in patients treated with pulmonary resection [41], thoracic radiation [42], cardiotoxic systemic agents [30, 31],...
and hormone therapy (both due to toxicity-related effects such as weakness and muscle wasting [43] and a potentially direct impact on cardiac function [44, 45]).

Another indirect impact of cancer lies in the need for various supportive medications in patients with cancer. Many individuals in this cohort are subject to polypharmacy irrespective of their specific anti-cancer regimen; these include the use of medications such as analgesics, aperients, and anti-emetics [46]. A large number of medications may preclude patients from receiving cardioprotective agents (e.g. beta blockers, angiotensin-converting enzyme inhibitors) due to drug-drug interactions, or clinician hesitance to add to an already significant pill burden. Some of these supportive drugs may also increase CVD risk independently. Steroids, for example, are commonly used in patients with cancer for the management of cancer-related complications such as nausea, and to reduce peritumoral oedema and inflammation [47]. Corticosteroids are well known to cause hypertension, hyperglycemia (often inducing diabetic or prediabetic states), dyslipidaemia, and obesity, especially in the high doses and long durations used in cancer, significantly increasing CVD risk [48].

The impact of shared etiological risk factors should also be acknowledged given that several modifiable risk factors can contribute to both cancer and CVD [49]. Smoking, physical inactivity, alcohol consumption, and poor nutrition are some of the most significant modifiable risk factors applicable to both conditions. It is estimated that elimination of these factors could help to prevent over 80% of heart disease, stroke, and type 2 diabetes, as well as 40% of malignancies [49]. Given these shared risk factors, the incidence of CVD in cancer survivors may be, at least in part, attributable to a patient’s lifestyle.

**Clinical Implications of Cancer-Related Cardiovascular Disease**

The clinical utility of investigating and subsequently treating CVD in cancer survivors lies in its impact on quality of life and mortality. This impact is aptly summarized by Scott et al. [50], who found that the predicted heart age of male and female cancer survivors was 8.5 and 6.5 years older, respectively, than their actual age. This calculation of heart age, derived from a 10-year cardiovascular disease risk estimate using the Framingham Risk Score, provides a simple picture of the implications of cancer-related CVD.

CVD, and chronic illness in general, is well known to be associated with impaired health-related quality of life in the general population. While there is a paucity of literature investigating long-term health-related quality of life in cancer survivors, there is some evidence to suggest impairment in some domains of health-related quality of life in cancer survivors is due to comorbid CVD [51]. Given that the majority of patients with cancer place at least equal weight on quality of life versus length of life [52], it is doubly important to identify and proactively manage CVD in these patients.

The link between CVD and mortality in cancer survivors is somewhat clearer. A 2020 analysis of over seven million patients with cancer revealed that CVD-related mortality is 2.24 times that of the general population (95% CI 2.23–2.25).
This risk decreases over the first year following a cancer diagnosis, but then increases over time [37]. Although a clear cause for the initial decrease in risk has not been established, it may be associated with the removal of the primary tumour and initial treatment resulting in attenuation of the risk from the cancer itself. Additionally, chemotherapy-induced thrombocytopenia may further attenuate this risk [53], as would the use of venous thromboembolism prophylaxis as a routine measure in higher risk patients [54]. For patients younger than 40 years, breast cancers and lymphomas carried the greatest risk of cardiovascular-related late mortality, whereas for those over 40 years, prostate, colorectal, breast, and lung cancers conferred the greatest risk [37]. An analysis of 628 breast cancer survivors supported this finding, demonstrating a hazard ratio of 1.79 (95% CI 1.53–2.09) for CVD risk compared to cancer-free controls [55]. A US study focusing on stroke revealed similar outcomes, with a 2019 analysis of Surveillance, Epidemiology, and End Results data showing a standardized mortality ratio of 2.17 (95% CI 2.15–2.19) in patients with cancer [56]. A third analysis of the same data indicated that CVD was the second most common cause of death amongst US cancer survivors who were more likely to die from CVD than the general population [57]. Ward et al. [58] explored this in greater detail in patients with endometrial cancer, showing that in patients with low-grade cancer, CVD posed the greatest mortality risk, although this may be confounded by the use of hormonal therapy in this cancer type and the fact that patients with low-grade cancer may receive higher doses of therapy given its curative intent. Weberpal et al. [59] in their analysis of breast cancer survivor data from the Surveillance, Epidemiology, and End Results database present a contrasting view to the previously described studies, demonstrating lower heart-related mortality when compared to the general population. The study’s strengths lie in its adjustment for competing risks and large sample size (n = 347,476), although it focuses on a specific subgroup of patients and its findings may therefore not be applicable to other cancer types [59]. In addition to not accounting for competing risks, other studies exploring CVD-related mortality in cancer survivors may also lack direct comparison with a cancer-free control group, limiting their ability to accurately capture the extent of the problem [60, 61]. These studies do, however, allow examination of cardiovascular mortality trends and prognostic factors associated with CVD-related death in cancer survivors.

Prevention, Screening, and Management of Cancer-Related Cardiovascular Disease

Perhaps the most compelling argument for investigating CVD in cancer survivors is the fact that it can be managed and, in some cases, prevented if identified early. Much of the preventative strategies focus on risk factor management (e.g. timely control of dyslipidaemia and treatment-induced diabetes, dietary and exercise interventions, blood pressure control) [49, 62]. Importantly, some anti-cancer therapies, such as radiotherapy [63] and hormone therapies [64], can play a role in the development of the metabolic syndrome and exacerbate pre-existing cardiovascular risk factors. While a balance must be maintained between ensuring adequate tumour control and minimizing adverse effects of treatment, sufficient consideration to mitigation of cardiovascular risk, particularly if the patient is responding well to treatment, is typically lacking. This may not be unreasonable in patients with incurable cancers whose life expectancy is predicted to be short. However, the advent of new, more effective cancer treatments has dramatically increased the life expectancy of patients with cancer, thereby demanding more proactive measures in reducing cardiovascular risk in this cohort.

Table 1 summarizes some of the options for prevention, screening, and management of cancer-related cardiovascular disease discussed below. Note that the evidence supporting each of these measures as effective for use in cancer survivors varies and is discussed further in “Screening and Cardiovascular Risk Stratification”, “Prevention and Management of Cardiovascular Disease”, and “Guidelines Regarding Cancer-Related Cardiovascular Disease Prevention and Management”.

Screening and Cardiovascular Risk Stratification

The 2020 European Society for Medical Oncology recommendations for the management of cardiac disease in cancer patients identify a number of timepoints at which screening for cardiac disease and risk factors should occur [65]. Similarly, the American Society of Clinical Oncology Clinical 2017 Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers provides recommendations for risk stratification and preventative strategies although notably focusing on the impact of treatment on ventricular dysfunction and heart failure, with little mention of atherosclerotic CVD [66]. Risk factor screening pre-treatment undoubtedly forms an important part of management [67, 68]. The European Society for Medical Oncology guidelines also suggests that baseline and intra-treatment measurement of cardiac biomarkers, such as troponin I and T [69, 70] and natriuretic peptides [71], may have some utility in identifying patients at high risk of developing cardiotoxicity from chemotherapy treatment, although the evidence for routine screening of biomarkers is not clear. However, baseline and intra-treatment electrocardiogram screening for QTc prolongation and evaluation of left ventricular ejection fraction, particularly in patients receiving cardiotoxic drugs, is recommended as a routine measure [65]. Global longitudinal strain, an early measure of cardiotoxicity with good diagnostic and prognostic utility,
is a newer measure assessed via echocardiogram that can be used in pre- and intra-treatment screening [72]. Notably, there is a lack of post-treatment recommendations for ongoing surveillance of cardiovascular risk in cancer survivors, with most recommendations focusing on pre- and intra-treatment strategies. Several programs, such as Passport for Care, exist for paediatric cancer survivors but such programs are rare in the adult population [73]. Broader guidelines for post-treatment care of cancer survivors generally neglect CVD surveillance, instead of focusing on monitoring for cancer recurrence. Long-term surveillance is particularly important given the ongoing risk of CVD extending well after active treatment.

Risk stratification plays an important role in the prevention and management of CVD in the general population. The American College of Cardiology and the American Heart Association (AHA) has developed both a 2019 guideline on the prevention of CVD [74] and a 2013 guideline for cardiovascular risk assessment [75], recommending the use of the Pooled Cohort Equations for estimation of atherosclerotic cardiovascular disease in the general population. The AHA’s Australian counterpart, the National Heart Foundation of Australia, has a guideline for the management of absolute CVD risk [76] along with a widely used online CVD risk calculator based on the Framingham Risk Eq. [77] The European Society of Cardiology’s 2021 guideline suggests the use of the SCORE2 (Systematic Coronary Risk Estimate 2) tool for risk stratification in healthy individuals [78]. However, there are no validated risk assessment tools, for survivors of adult cancer [79]. Several organizations have developed consensus statements on risk assessment in specific cancer types and treatment modalities, but there is no broad recognition of the impact of cancer and cancer treatment on CVD risk in survivors of cancer in these statements.

Kolominsky et al. [79] suggest that in the absence of such guidelines, the AHA Life’s Simple 7 framework can be used as a tool for CVD risk stratification and counselling in survivors while recognizing that these tools do not account for cancer-related cardiovascular risk, nor the significant impact of specific anti-cancer treatment modalities. Mohammed et al. [80] suggest that such risk calculators severely underestimate cardiovascular risk in cancer survivors, and that these patients should therefore receive aggressive risk factor modification even if their risk score using conventional tools is ‘low’.

### Prevention and Management of Cardiovascular Disease

In addition to screening tools and risk stratification, several interventions that can reduce CVD incidence in cancer survivors also exist and include rehabilitation and exercise interventions, optimization of nutrition, and cardiovascular-specific therapeutics.

The concept of “prehabilitation” is an increasingly popular strategy to mitigate the risk of decline during cancer treatment [8], and provides a safe, low-cost avenue to prevent CVD in survivors. Amongst several types of prehabilitation, high-intensity interval training is associated with improvement of vascular function [81] and peak oxygen consumption [82], the latter being strongly linked to cardiovascular mortality [83]. The recently published ERASE trial demonstrated improved cardiorespiratory fitness following a 12-week high-intensity interval training program in patients with prostate cancer under active surveillance, providing some evidence for a benefit of exercise in those not undergoing treatment [84]. Exercise both during and after
cancer treatment can also improve cardiorespiratory fitness and CVD outcomes [85].

Dietary intervention is another avenue being investigated for its efficacy in decreasing CVD incidence. There is increasing evidence supporting the optimization of nutrition for improvement of long-term outcomes and mortality in cancer survivors [8], although there is limited evidence for reduction of cardiovascular risk specifically. Conversely, the Alliance A011401 trial is currently exploring the impact of caloric restriction and physical activity on CVD incidence as a secondary outcome in breast cancer survivors and may provide some insight into the efficacy of dietary interventions [86].

Drug treatments which modify cardiovascular risk factors may also play a role in attenuating CVD risk in cancer survivors. Given the ability of several chemotherapeutic agents, particularly VEGF-inhibitors [87], to induce hypertension, it may be reasonable to employ the use of anti-hypertensives such as dihydropyridine calcium channel blockers [88]; however, there is little evidence supporting the use of one anti-hypertensive agent over another. There is also some evidence supporting the cardioprotective effects of statin treatment in patients treated with anthracyclines [89], although these benefits have not been explored in cohorts not exposed to cardiotoxic chemotherapy. As with ECG screening, these interventions have a pre- and intra-treatment focus, and typically do not extend beyond the treatment period.

It is also worth considering the role of treatment modifications in reducing cardiovascular risk. For example, the administration of doxorubicin in PEGylated liposomal form can reduce anthracycline-mediated cardiotoxicity [90]. Concurrent administration of dexrazoxane during anthracycline treatment may also provide cardioprotection in specific cancer types and age demographics [91]. Of note, the use of remote ischemic conditioning, subjecting tissue remote from the heart to brief, reversible episodes of ischaemia and subsequent reperfusion, is a low-cost novel intervention that has been proposed for use in patients with cancer to prevent anthracycline-mediated toxicity [92]. While this technique is currently only evidenced in animal models [93, 94], the ongoing ERIC-ONC trial [95] and RESILIENCE trial [96] may provide some evidence for the use of remote ischemic conditioning in human patients with cancer receiving anthracycline-based treatment. For those treated with thoracic radiation, the use of advanced radiation techniques such as stereotactic ablative radiotherapy and/or dose reductions may additionally be considered, although Cutter et al. [97] suggest that individual risk assessment is required to determine whether this is appropriate. Similarly, proton therapy has been shown to be effective in reducing the cardiac impact of radiation [98]. Patient-based techniques have also shown benefits for cardiac sparing: these include deep inspiration breath holds [99] and prone positioning [100].

### Guidelines Regarding Cancer-Related Cardiovascular Disease Prevention and Management

Beyond the 2020 European Society for Medical Oncology recommendations for the management of cardiac disease in cancer patients throughout oncological treatment [65] and a 2016 European Society of Cardiology position paper on cardiovascular toxicity [101], there are few evidence-based guidelines that provide recommendations for preventing and managing CVD risk in long-term survivors of cancer. The AHA has recognized the need for cardio-oncology rehabilitation [102] given the intersection between breast cancer and CVD [67], but has not published any specific guidelines. There is some mention of the field of cardio-oncology in the National Comprehensive Cancer Network’s 2018 Survivorship Clinical Practice guidelines, but there is a focus on anthracycline-induced cardiac toxicity [103]. Notably, the newly created Australia and New Zealand Cardio-Oncology Registry will track cardiac dysfunction related to cancer therapy as well as interventions targeting its prevention, although the registry will predominantly focus on chemotherapy-induced cardiotoxicity [104]. Future guidelines should take a more holistic approach, providing recommendations to prevent CVD in all cancer survivors irrespective of whether they have been exposed to known cardiotoxic treatments. The inclusion of recommendations for post-treatment care and ongoing long-term screening would also allow all cancer survivors to receive appropriate cardiac follow-up.

### Challenges Investigating Cardiovascular Risk in Adult Cancer Survivors

There are several variables that can be difficult to assess in the analysis due to data availability. For example, it can be difficult to separate the impact of a cancer itself and cancer treatment. Much of the large-scale research in adult cardio-oncology makes use of national registry–based data to assess CVD incidence and mortality [9–12]. While some of these registries capture limited treatment data, very rarely is specific treatment modality, dosage, and duration data recorded. Without such treatment data, it can be difficult to determine whether CVD risk in cancer survivors is a result of the patient’s cancer, the treatment they have received, or a combination of both. In a similar vein, detailed cancer stage data is often not available in registries or cohort studies. Given the evidence that metastatic disease may confer greater CVD risk than local cancers [9, 24], a lack of staging data can limit analyses. Data on baseline cardiovascular risk, relevant comorbidities (e.g. dyslipidaemia, hypertension, diabetes), and shared risk factors (e.g. smoking, physical inactivity,
alcohol consumption, poor nutrition) must also be available to allow for an accurate assessment of the impact of cancer on CVD incidence. Data on mortality events is similarly important to adjust for death as a competing risk.

We must also consider that as cancer treatment evolves, the CVD risk posed by treatments changes. Some modalities, such as radiotherapy, have conferred less risk over time. Mulrooney et al. [105] report that modifications in modern radiation protocols resulted in a reduced risk of coronary artery disease from the 1970s to the 1990s. Although this study was conducted in adult survivors of childhood cancers, it nonetheless illustrates that treatment-induced CVD risk can improve over time. In adult patients with breast cancer, the mean cardiac radiation dose has decreased from 13.3 Gy in the 1970s to 2.3 Gy in 2006 [106]. Conversely, newer chemotherapeutic classes such as certain targeted therapies [107] have been found to pose increased CVD risk when compared to some older agents. Without detailed cancer treatment data, it is difficult for studies to account for the varying impact of different treatment modalities and protocols on CVD risk and incidence.

The requirement for long-term follow-up to accurately assess CVD risk also makes cardio-oncology research difficult. As previously described, coronary heart disease risk can remain elevated even 10 years following a cancer diagnosis [10]. Similarly, stroke risk is highest during the first 6 months post-cancer diagnosis but remains elevated for 10 years post-diagnosis [9]. The risk of some events, such as heart failure and cardiomyopathy, can even continue to increase over 12+ years [11]. Retrospective analysis of cancer registries can provide meaningful data with minimal logistical burden, facilitating large sample sizes and long follow-up time. The alternative, prospective studies, provide a greater level of evidence but require considerable funding to maintain follow-up over a decade-long period.

The predominance of paediatric cohorts in cardio-oncology research should also be noted. The Childhood Cancer Survivor Study (CCSS) provided valuable data in establishing a link between childhood cancer and CVD. Mulrooney et al. [108] found that childhood cancer survivors from the CCSS were more likely than their cancer-free siblings to experience congestive heart failure (hazard ratio [HR] 5.9, 95% CI 3.4–9.6), myocardial infarction (HR 5.0, 95% CI 2.3–10.4), pericardial disease (HR 6.3, 95% CI 3.3–11.9), and valvular disease (HR 4.8, 95% CI 3.0–7.6), with anthracyclines and cardiac radiation conferring the greatest risk.

The CCSS, in combination with several other studies which support the increased CVD risk in childhood cancer survivors [109], laid the groundwork for evidence-based CVD risk prediction models in childhood cancer survivors [110] and guidelines for long-term follow-up in this cohort [111]. The fact that adult cardio-oncology is a much newer field has meant that it is some way behind its paediatric equivalent in regard to a comprehensive literature base and the presence of evidence-based guidelines.

Table 2 summarizes the challenges in investigating cardiovascular risk discussed in this section.

### Future Directions

Cardio-oncology is a rapidly evolving field and is supported by several large-scale studies confirming the impact of cancer on subsequent CVD. However, more studies in adult cohorts with extensive follow-up periods are required to inform evidence-based guidelines on recommendations for post-treatment screening and management in adult cancer survivors. Although an abundance of research exists exploring long-term CVD outcomes in childhood cancer survivors, the majority of diagnoses are hematological in nature, with less than half of all diagnosed cancers in the CCSS being solid tumours [112], limiting the generalizability of this data to an adult survivor population that suffers from vastly different types of cancers with different underlying mechanisms and different anti-cancer therapies.

Future research investigating the link between CVD and cancer in adult cancer survivors must aim to account for shared risk factors, different treatment modalities, doses, and durations, the variation in risk across both cancer types and stages, and competing risks. In doing so, factors that increase susceptibility to the cardiotoxic effects of cancer and cancer treatment can be identified and subsequently used to identify high-risk patients. The literature must also be updated as new treatment protocols and modalities are introduced, given that each type of treatment carries with it a different CVD risk.

| Table 2 | Challenges in investigating cardiovascular risk in cancer survivors |
| --- | --- |
| • Separating the impact of cancer treatment from the impact of the cancer itself |
| • Disentangling the impact of cancer and cancer treatment from that of shared risk factors (e.g. smoking, diet, physical activity, comorbidities) and normal ageing |
| • Adjusting for cancer-related factors in analysis that are often not available in databases (e.g. cancer treatment, cancer stage) |
| • Adjusting for non-cancer-related factors in analysis (e.g. shared risk factors, comorbidities, competing risk of death) |
| • Adjusting for the changing cardiovascular risk posed by cancer treatments as these treatments evolve over time |
| • Ensuring appropriate follow-up to capture late cardiovascular effects of treatment |
| • Capturing data in adult cohorts in a field where much of the data is in paediatric cohorts |
Table 3  Future directions for cardio-oncology in research and clinical practice

Opportunities for research: cardiovascular disease (CVD) incidence and driving mechanisms
• Investigate CVD risk in adult cancer survivor cohorts with adjustment for shared risk factors, cancer-related variables, anti-cancer treatment, and competing risks
• Explore long-term risk of CVD in cancer survivors using longitudinal follow-up
• Explore cancer-related mechanisms driving CVD in cancer survivors, both direct cancer- and treatment-related

Opportunities for research: screening and interventions
• Investigate utility of routine pre- and intra-treatment CVD screening strategies for CVD in cancer survivors
• Conduct randomized-controlled trials investigating the role of prevention and management of CVD during active treatment on CVD in cancer survivors
• Investigate post-treatment CVD surveillance programs for adult cancer survivors
• Investigate strategies for active intervention in cancer survivors through pragmatic clinical trials

Opportunities for clinical practice
• Publish guidelines for screening, prevention, and management of CVD in cancer survivors both pre- and post-treatment
• Train healthcare professionals in managing CVD risk in cancer survivors, along with educating patients about their individual risk profile
• Encourage a multi-disciplinary approach to cancer survivorship care with input from medical specialists, primary care providers, and allied health professionals
• Include CVD screening in routine long-term cancer survivor surveillance programs
• Implement evidence-based interventions (e.g. dietary and exercise programs, risk factor management) to mitigate CVD risk in cancer survivors

Randomized-controlled trials investigating CVD screening tools and interventions in adult cancer survivor cohorts are also vital, although this can be difficult given the need for long-term follow-up in capturing CVD risk. Without this research, it is difficult to determine how best to screen for cardiovascular disease in cancer survivors, as well as when to intervene prophylactically. Furthermore, while pre- and intra-treatment care is important, there is undoubtedly a gap in the post-treatment space. The utility in post-treatment care lies in the opportunity to reduce comorbidity burden, improve quality of life, and reduce cardiovascular mortality. The efficacy of common CVD risk factor modification treatments (e.g. statins, anti-hypertensives) in adult cancer survivor cohorts should also be validated.

Ultimately, the greatest gap in cardio-oncology is the lack of evidence-based guidelines for long-term CVD prevention and management in cancer survivors. For clinicians to incorporate routine surveillance for, and preventative management of, CVD in the care of cancer survivors, evidence-based recommendations need to be generated by national and international oncology and cardiology organizations. In addition to guidelines, adequate training must be provided to cancer specialists and primary care physicians to ensure that they are well-informed about the CVD risks in cancer survivors. This should extend beyond pre-treatment screening and intra-treatment surveillance for treatments known to be cardiotoxic and recognize the long-term risk of CVD posed by all cancer types and treatment modalities. A multi-disciplinary approach to cardio-oncology is also vital, requiring input from not only cancer specialists but also other healthcare professionals including primary care physicians, cardiologists, and allied health professionals, in order to provide appropriate, specialized cardiovascular care to cancer survivors.

Table 3 summarizes some of the options for future research and changes to clinical practice for cardio-oncology.

Conclusion
Cancer and cancer treatment can accelerate aging, of which CVD is a common sequela. There is evidence supporting a link between cancer and increased risk of cardiovascular disease, which can remain elevated for up to a decade post-diagnosis, along with reductions in quality of life and increases in mortality. Some strategies exist to mitigate this risk and treat CVD in cancer survivors but given the relative youth of the field of cardio-oncology, there are few evidence-based recommendations from professional organizations surrounding the management of CVD in this cohort. Evidence-based clinical guidelines for the management of cancer-associated cardiovascular disease and a multi-disciplinary effort in cardio-oncology research, education, and clinical care are required to improve cardiovascular outcomes for cancer survivors.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s11912-022-01309-w.

Funding  Open Access funding enabled and organized by CAUL and its Member Institutions This work was supported by grants from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (P30 CA047904, U01 AG029824, U19 AG062682, 3U19 AG062682-02S1); grants from the National Health and Medical Research Council of Australia (334047, 1127060); Monash University; and the Victorian Cancer Agency. The funders played no role in the conceptualization, writing, or editing of the manuscript.
Declarations

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. DiLoreto R, Murphy CT. The cell biology of aging. Mol Biol Cell. 2015;26(25):4524–31. https://doi.org/10.1091/mbc.E14-06-1084.

2. Maynard S, Fang EF, Scheibye-Knudsen M, Croteau DL, Bohr VA. DNA damage, DNA repair, aging, and neurodegeneration. Cold Spring Harb Perspect Med. 2015;5(10). https://doi.org/10.1101/cshperspect.a025130.

3. Smetana K Jr, Lacinia L, Szabo P, Dvorankova B, Broz P, Sedo A. Ageing as an important risk factor for cancer. Anticancer Res. 2016;36(10):5009–17. https://doi.org/10.21873/anticanres.11069.

4. Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, Fuldner R, Ferrucci L, Gallicchio L, Gavrilov L, et al. Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst. 2019;111(12):1245–54. https://doi.org/10.1093/jnci/djz136. This paper outlines the discussions from a think tank convened by the National Cancer Institute in 2018 that called for greater research into accelerated aging in cancer survivors.

5. Muhandirage J, Orchard S, Haydon A, Zalcberg J. The acceleration of ageing in older patients with cancer. J Geriatr Oncol. 2021;12(3):343–51. https://doi.org/10.1016/j.jgo.2020.09.010.

6. Giza DE, Iliessou G, Hassan S, Marmagkiolis K, Iliescu C. Cancer as a risk factor for cardiovascular disease. Curr Oncol Rep. 2017;19(6):39. https://doi.org/10.1007/s11912-017-0601-x.

7. Cardiovascular diseases (CVDs): World Health Organisation; 2021 [cited 2 August]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-cvds). Accessed 2 Aug 2021.

8. Guida JL, Agurs-Collins T, Ahles TA, Campisi J, Dale W, Demark-Wahnefried W, Dietrich J, Fuldner R, Gallicchio L, Green PA, et al. Strategies to prevent or remediate cancer and treatment-related aging. J Natl Cancer Inst. 2021;113(2):112–22. https://doi.org/10.1093/jnci/djaa060.

9. Zoller B, Ji J, Sundquist J, Sundquist K. Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer. 2012;48(12):1875–83. https://doi.org/10.1016/j.ejca.2012.01.005. This study was one of the first large-scale analyses (n = 820,491) investigating stroke in patients with cancer.

10. Zoller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer. 2012;48(1):121–8. https://doi.org/10.1016/j.ejca.2011.09.015. This study was one of the first large-scale analyses (n = 820,491) investigating coronary heart disease in patients with cancer.

11. Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, Dos-Santos-Silva I, Smeeth L, Bhaskaran K. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394(10203):1041–54. https://doi.org/10.1016/S0140-6736(19)31674-5. This study is a recent (2018) large-scale analysis (n = 108,215) of various cardiovascular diseases and outcomes in cancer survivors.

12. Schoormans D, Vissers PAJ, van Herk-Sukel MPP, Denollet J, Pedersen SS, Dalton SO, Rottmann N, van de Poll-Franse L. Incidence of cardiovascular disease up to 13 year after cancer diagnosis: a matched cohort study among 32 757 cancer survivors. Cancer Med. 2018;7(10):4952–63. https://doi.org/10.1002/cam4.1754.

13. Paterson DL, Wiebe N, Cheung WY, Mackey JR, Pitskin E, Reiman A, Tonelli M. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. JACC CardioOncol. 2022;4(1):85–94. https://doi.org/10.1016/j.jaccou.2022.01.100. This study is a very recent (2022) large-scale analysis of various cardiovascular diseases and outcomes in cancer survivors. The sample size in this study is one of the largest of its kind (n = 4,519,243) and it was also benefited by its adjustment for various cardiovascular comorbidities.

14. Zhang F, Wang K, Du P, Yang W, He Y, Li T, Mei Z. Risk of stroke in cancer survivors: a meta-analysis of population-based cohort studies. Neurology. 2021;96(4):e513–e26. https://doi.org/10.1212/WNL.0000000000012164. This meta-analysis combined the results of 21 cohort studies and provides a very clear picture of increased risk of stroke in cancer survivors.

15. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.

16. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. https://doi.org/10.1038/nature07205.

17. Hart PC, Rajab IM, Alebraheem M, Potempa LA. C-reactive protein and cancer-diagnostic and therapeutic insights. Front Immunol. 2020;11:595835. https://doi.org/10.3389/fimmu.2020.595835.

18. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, Scadden DT, Wagner D. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–81. https://doi.org/10.1073/pnas.1200419109.

19. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740. https://doi.org/10.4061/2011/394740.

20. Park SJ, Bejar R. Clonal hematopoiesis in cancer. Exp Hematol. 2020;83:105–12. https://doi.org/10.1016/j.exphem.2020.02.001.

21. Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137–44. https://doi.org/10.1038/s41569-019-0247-5.
22. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvaider E, McConkey M, Gupta N, Gabriel S, Ardissino D, et al. Clonal hematopoiesis and risk of atherothrombotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21. https://doi.org/10.1056/NEJMoa1701179.

23. Dardiotis E, Aloizou AM, Markoula S, Siokas V, Tsrouhah K, Tzanakakis G, Libra M, Kyritsis AP, Brotsis AG, Aschner M, et al. Cancer-associated stroke: pathophysiology, detection and management (Review). Int J Oncol. 2019;54(3):779–96. https://doi.org/10.3892/ijo.2019.4669.

24. Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MS, Panagases KS, DeAngelis LM. Association between incident cancer and subsequent stroke. Ann Neurol. 2015;77(2):291–300. https://doi.org/10.1002/ana.24325.

25. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106. https://doi.org/10.1016/S0140-6736(05)67887-7.

26. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270(16):1949–55.

27. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RT0G 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99. https://doi.org/10.1016/S1470-2247(14)71207-0.

28. Koutroumpakis E, Palaskas NL, Lin SH, Abe JI, Liao Z, Banchs J, Deswal A, Yusuf SW. Modern radiotherapy and risk of cardiotoxicity. Chemotherapy. 2020;65(3–4):65–76. https://doi.org/10.1159/000510573.

29. Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Planca JC, Volgman AS, Moseley KF, Porter CB, Ismail-Khan R, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14(3):e000082. https://doi.org/10.1161/CIRG.0000000000000802.

30. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302. https://doi.org/10.2165/00002018-20002204-00002.

31. Blaes AH, Thavendiranathan P, Moslehi J. Cardiac toxicities in the era of precision medicine: underlying risk factors, targeted therapies, and cardiac biomarkers. Am Soc Clin Oncol Educ Book. 2018;38:764–74. https://doi.org/10.1200/EDBK_208509.

32. Huang R, Zhou Y, Hu S, Ren G, Cui F, Zhou PK. Radiotherapy exposure in cancer patients and subsequent risk of stroke: a systematic review and meta-analysis. Front Neurol. 2019;10:233. https://doi.org/10.3389/fneur.2019.00233.

33. Saynak M, Cosar-Alas R, Yurtu-Caloglu V, Caloglu M, Kocak Z, Uzal C. Chemotherapy and cerebrovascular disease. J BUON. 2008;13(1):31–6.

34. Periard D, Boulangier CM, Eyer S, Amable N, Pugin P, Gerlicher C, Hayoz D. Are circulating endothelial-derived and platelet-derived microparticles a pathogenic factor in the cisplatin-induced stroke? Stroke. 2007;38(5):1636–8. https://doi.org/10.1161/STROKEAHA.106.479733.

35. Fairev S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25–35. https://doi.org/10.1200/JCO.2005.02.2194.

36. Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M, Halter J, Meyer-Monard S, Heim D, Tsakiris DA, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110(9):3463–71. https://doi.org/10.1182/blood-2006-10-054080.

37. Stoltzfus KC, Zhang Y, Seurong K, Sinoway LI, Trifiletti DM, Chinchilli VM, Zaorsky NG. Fatal heart disease among cancer patients. Nat Commun. 2020;11(1):2011. https://doi.org/10.1038/s41467-020-15639-5. This 2020 analysis of over seven million patients with cancer showed that this cohort had nearly double the risk of cardiovascular-related mortality compared to the general population.

38. Jones LW, Eves ND, Haykowski M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009;10(6):598–605. https://doi.org/10.1016/S1470-2247(09)70031-2.

39. Young DR, Hivert MF, Alhassan S, Camhi SM, Ferguson JF, Katzmarzyk PT, Lewis CE, Owen N, Perry CK, Siddique J, et al. Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association. Circulation. 2016;134(15):e262–79. https://doi.org/10.1161/CIR.0000000000000440.

40. Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowski M, Joy AA, Courneyea KS, Tankel K, Spratlin J, Reiman T. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer. 2007;55(2):225–32. https://doi.org/10.1016/j.lungcan.2006.10.006.

41. Brunelli A, Xiume F, Refai M, Salati M, Marasco R, Sciarra V, Sabbatini A. Evaluation of expectancy volume, diffusion capacity, and exercise tolerance following major lung resection: a prospective follow-up analysis. Chest. 2007;131(1):141–7. https://doi.org/10.1378/chest.06-1345.

42. Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63(1):214–23. https://doi.org/10.1016/j.ijrobp.2005.01.029.

43. Winters-Stone KM, Moe E, Graff JN, Dieckmann NF, Stoyles S, Borsch C, Alumkal JJ, Amling CL, Beer TM. Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy. J Am Geriatr Soc. 2017;65(7):1414–9. https://doi.org/10.1111/jgs.14795.

44. Marsh JD, Lehmam MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98(3):256–61. https://doi.org/10.1161/01.cir.98.3.256.

45. Jones LW, Haykowski MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50(15):1435–41. https://doi.org/10.1016/j.jacc.2007.06.037.

46. Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–22. https://doi.org/10.1634/theoncologist.2009-0290.

47. Wooldridge JD, Anderson CM, Perry MC. Corticosteroids in advanced cancer. Oncology (Williston Park). 2001;15(2):225–34, discussion 34-6.

48. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16(4):505–11. https://doi.org/10.1161/jpix.1997.1159.

49. Epping-Jordan JE, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. Lancet. 2005;366(9497):1667–71. https://doi.org/10.1016/S0140-6736(05)67342-4.

50. Scott LC, Yang Q, Dowling NF, Richardson LC. Predicted heart age among cancer survivors — United States, 2013–2017.
MMWR Morb Mortal Wkly Rep. 2021(70):1–6. https://doi.org/10.15585/mmwr.mm7001a1.

51. van de Poll-Franse LV, Kwan L, Reiter RE, Lee SP, Liitwen MS. The influence of cardiovascular disease on health related quality of life in men with prostate cancer: a 4-year followup study. J Urol. 2008;179(4):1362–7; discussion 7. https://doi.org/10.1016/j.juro.2007.11.086.

52. Meropol NJ, Egleston BL, Buzaglo JS, Benson AB 3rd, Cegala DJ, Diefenbach MA, Fleisher L, Miller SM, Sulmasy DP, Weinfurt KP, et al. Cancer patient preferences for quality and length of life. Cancer. 2008;113(12):3459–66. https://doi.org/10.1002/cncr.23968.

53. Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Ane-mia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007. Clin Ther. 2009;31(Pt 2):2416–32. https://doi.org/10.1016/j.clinthera.2009.11.020.

54. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khora-na AA, Leavitt AD, Lee AYH, Macbeth F, Morgan RL, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74. https://doi.org/10.1182/bloodadvances.2020003442.

55. Ramin C, Schaeffer ML, Zheng Z, Connor AE, Hoffman-Bolton J, Lau B, Visvanathan K. All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. J Natl Cancer Inst. 2021;113(2):137–45. https://doi.org/10.1093/jnci/djaa096.

56. Zaorsky NG, Zhang Y, Tchelebi LT, Mackley HB, Chinichili VM, Zacharia BE. Stroke among cancer patients. Nat Commun. 2019;10(1):5172. https://doi.org/10.1038/s41467-019-13120-6.

57. Sturgeon KM, Deng L, Blumenthm SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97. https://doi.org/10.1093/euheat/jez766.

58. Ward KK, Shah NR, Saenz CC, McMahon MT, Alvarez EA, Plax SC. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012;126(2):176–9. https://doi.org/10.1016/j.ygyno.2012.04.013.

59. Weberpals J, Jansen L, Muller OJ, Brenner H. Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. 2018;39(43):3896–903. https://doi.org/10.1093/eurheartj/ehz676.

60. Herrero Rivera D, Nieto-Guerrero Gomez JM, Fernandez Cacicedo, de Bobadilla J, Delgado D, Rivin Del Campo E, Praena-Fernandez JM, Bernabe Caro R, Ortiz Gordillo MJ, Fernandez-Fernandez MC, Lopez Guerra JL. Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment. Clin Transl Oncol. 2019;21(9):1220–30. https://doi.org/10.1007/s12094-019-02047-5.

61. Sun JY, Zhang ZY, Qu Q, Wang N, Zhang YM, Miao LF, Wang J, Wu LD, Liu Y, Zhang CY, et al. Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer. Int J Cardiol. 2021;330:186–93. https://doi.org/10.1016/j.ijcard.2021.02.025.

62. Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012;22(17):R741–52. https://doi.org/10.1016/j.cub.2012.07.024.

63. van Waas M, Nuggers SJ, Raat H, van Rij CJM, Pieters R, van den Heuvel-Eibrink MM. Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblas-toma survivors. PLoS ONE. 2012;7(12):e52237. https://doi.org/10.1371/journal.pone.0052237.

64. Redig AJ, Munshi HG. Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med. 2010;123(1):87 e1–6. https://doi.org/10.1016/j.amjmed.2009.06.022.

65. Curigliano G, Lenihan D, Fradley M, Gnarra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. https://doi.org/10.1016/j.annonc.2019.10.023. This consensus statement by the European Society for Medical Oncology provides recommendations for intra-treatment screening and management of cardiovascular disease in patients with cancer.

66. Arsenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. https://doi.org/10.1200/JCO.2016.70.5400.

67. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–66. https://doi.org/10.1161/CIR.0000000000005556.

68. Bhutia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiac disease in patients with prostate cancer. Circulation. 2016;133(5):537–41. https://doi.org/10.1161/CIRCULATIONAHA.115.012519.

69. Killickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. 2005;16(5):798–804. https://doi.org/10.1093/annonc/mdi152.

70. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54. https://doi.org/10.1161/01.CIR.0000039265.71766.CC.

71. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinsiefer J, Noe J, Lauer S, Al-Sakkaf N, Piccart-Gebhart MJ, de Azambuja E. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study: a multicenter randomised controlled trial. J Clin Oncol. 2017;35(8):878–84. https://doi.org/10.1200/JCO.2015.65.7916.

72. Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in cardiac- oncology. JACC CardioOncol. 2020;2(5):677–89. https://doi.org/10.1001/jco.2020.0.1011.

73. Horowitz ME, Fordis M, Krause S, McKellar J, Poplack DG. Passport for care: implementing the survivorship care plan. J Oncol Pract. 2009;5(3):110–2. https://doi.org/10.1200/JOP.0934405.

74. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberg ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–646. https://doi.org/10.1161/CIR.0000000000007678.
CI, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73. https://doi.org/10.1161/CIR.00000437741.48606.98. This guideline outlines strategies for assessment of cardiovascular risk, although it similarly does not explicitly refer to strategies for cancer survivors.

76. Guidelines for the management of absolute cardiovascular disease risk. National Vascular Disease Prevention Alliance; 2012. https://www.heartfoundation.org.au/getmedia/4342a70f-4487-9e0-bb8b-aa33a47fcb2/Absolute-CVD-Risk-Full-Guidelines_2.pdf.

77. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med. 1990;322(23):1635–41. https://doi.org/10.1056/NEJM19900707222304.

78. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Bifi A, Boavida JM, Capodanno D, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. https://doi.org/10.1093/eurheartj/ehab484.

79. Kolominsky J, Bottinor W, Rifai M, Abbate A, Virani S, Patel J. ASCVD risk stratification among cancer survivors. American College of Cardiology: Latest in Cardiology; 2021. https://www.acc.org/latest-in-cardiology/articles/2021/05/10/42/ascvd-risk-stratification-among-cancer-survivors.

80. Mohammed T, Parekh T, Desai A. Cardiovascular risk management in cancer survivors: are we doing it right? World J Clin Oncol. 2021;12(3):144–9. https://doi.org/10.5306/wjco.v12.i3.144.

81. Ramos JS, Dalleck LC, Tjonna AE, Beetham KS, Coombes J. The impact of high-intensity interval training versus moderate-intensity continuous training on vascular function: a systematic review and meta-analysis. Sports Med. 2015;45(5):679–92. https://doi.org/10.1007/s00277-015-0321-z.

82. Palma S, Hasenoehrl T, Jordiakieva G, Ramazanova D, Crevenna R. High-intensity interval training in the prehabilitation of cancer patients-a systematic review and meta-analysis. Support Care Cancer. 2021;29(4):1781–94. https://doi.org/10.1007/s00520-020-05834-x.

83. O’Donovan G, Lee IM, Hamer M, Stamatakis E. Association of “weekend warrior” and other leisure time physical activity patterns with risks for all-cause, cardiovascular disease, and cancer mortality. JAMA Intern Med. 2017;177(3):335–42. https://doi.org/10.1001/jamainternmed.2016.8014.

84. Kang DW, Fairey AS, Boule NG, Field CJ, Wharton SA, Cournaye KS. Effects of exercise on cardiorespiratory fitness and biochemical progression in men with localized prostate cancer under active surveillance: the ERASE randomized clinical trial. JAMA Oncol. 2021. https://doi.org/10.1001/jamaoncol.2021.3067. This randomised controlled trial showed the benefits of high-intensity interval training for improving cardiorespiratory fitness in patients with prostate cancer.

85. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, Moskowitz CS, Matsoukas K, Iyengar NM, Dang CT, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36(22):2297–305. https://doi.org/10.1200/JCO.2017.77.5809.

86. Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, et al. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017;3:37. https://doi.org/10.1038/s41523-017-0040-8.

87. Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120–7. https://doi.org/10.1016/j.ctrv.2016.12.002.

88. Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keele S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, et al. Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma. Circ Heart Fail. 2018;11(3):e004408. https://doi.org/10.1161/CIRCHEARTF AILURE.117.004408.

89. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384–90. https://doi.org/10.1016/j.jacc.2012.07.067.

90. O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9. https://doi.org/10.1093/annonc/mdh097.

91. Bansal N, Adams MJ, Ganatra S, Colan SD, Aggarwal S, Steiner R, Amdani S, Liphsultz ER, Liphsultz SE. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-oncology. 2019;5:18. https://doi.org/10.1186/s40595-019-0054-5.

92. Haansenloy Derek J, Ng Choon T, Chong Jun H. Repeated remote ischemic conditioning protects against doxorubicin cardiotoxicity. JACC CardioOncol. 2020;2(1):53–5. https://doi.org/10.1016/j.jacco.2020.02.001.

93. He Q, Wang F, Ryan TD, Chalasani M, Redington AN. Repeated remote ischemic conditioning reduces doxorubicin-induced cardiotoxicity. JACC CardioOncol. 2020;2(1):41–52. https://doi.org/10.1016/j.jacco.2020.01.005.

94. Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, Molina-Iracheta AD, Pérez-Martínez C, García RD, González-Calle D, et al. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res. 2020;117(4):1132–43. https://doi.org/10.1093/cvr/cvaa181.

95. Chung R, Maulik A, Hamarneh A, Hochhauser D, Hausenloy DJ, Walker JM, Yellon DM. Effect of remote ischemic preconditioning in oncology patients undergoing chemotherapy: rationale and design of the ERIC-ONC study—a single-center, blinded, randomized controlled trial. Clinical Cardiol. 2016;39(2):72–82. https://doi.org/10.1002/clc.22507.

96. RESILIENCE, a project to reduce the prevalence of heart failure in cancer survivors [press release]. European Society of Cardiology; 2021. https://www.escardio.org/The-ESC/Press-Office/Press-releases/RESILIENCE-a-project-to-reduce-the-prevalence-of-heart-failure-in-cancer-survivors.

97. Cutter DJ, Ramroth J, Diez P, Buckle A, Ntetas G, Popova B, Clifton-Hadley L, Hoskin PJ, Darby SC, Radford J, et al. Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography-directed therapy for early-stage Hodgkin lymphoma. J Clin Oncol. 2021;JCO2100408. https://doi.org/10.1200/JCO.21.00408.

98. Frankert AJ, Nagarajan R, Pater L. The impact of proton therapy on cardiotoxicity following radiation treatment. J Thoram Thrombolysis. 2021;51(4):877–83. https://doi.org/10.1007/s11239-020-02303-4.

99. Bergom C, Currey A, Desai N, Tai A, Strauss JB. Deep inspiration breath hold: techniques and advantages for cardiac sparing during breast cancer irradiation. Front Oncol. 2018;8:87. https://doi.org/10.3389/fonc.2018.00087.
100. Huppert N, Jozsf G, Dewyngaert K, Formenti SC. The role of a prone setup in breast radiation therapy. Front Oncol. 2011;1:31. https://doi.org/10.3389/fonc.2011.00031.

101. • Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. https://doi.org/10.1093/eurheartj/ehw211. This position paper provides recommendations from the European Society of Cardiology for managing cardiovascular toxicity secondary to cancer treatment.

102. • Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, La Gerche A, Ligibel JA, Lopez G, Madan K, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Assoc Circ. 2019;139(21):e997-e1012. https://doi.org/10.1161/CIR.0000000000000679. This statement from the American Heart Association acknowledges the need for cardio-oncology rehabilitation.

103. Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, et al. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16(10):1216–47. https://doi.org/10.6004/jnccn.2018.0078. This guideline from the National Comprehensive Cancer Network briefly provides recommendations for cardiac care in cancer survivors, although it has a focus on treatment-induced toxicity.

104. Lapirow D, La Gerche A, Toro C, Masango E, Costello B, Porello E, Ludlow L, Marshall G, Trahair T, Mateos M, et al. The Australia and New Zealand Cardio-Oncology Registry: evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients. Intern Med J. 2021;51(2):229–34. https://doi.org/10.1111/imj.14719.

105. Mulrooney DA, Hyun G, Ness KK, Ehrhardt MJ, Yasui Y, Duprez D, Howell RM, Leisenring WM, Constine LS, Tomorozos E, et al. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. BMJ. 2020;368:m6794. https://doi.org/10.1136/bmj.m6794.

106. Piroth MD, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Krug D, et al. Heart toxicity from breast cancer radiotherapy: current findings, assessment, and prevention. Strahlenther Onkol. 2019;195(1):1–12. https://doi.org/10.1007/s00066-018-1378-z.

107. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12. https://doi.org/10.1200/JCO.2007.15.6331.

108. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606. https://doi.org/10.1136/bmj.b4606.

109. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, Hudson MM, Kremer LC, Landy DC, Miller TL, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–95. https://doi.org/10.1161/CIR.0b013e3182a8099.

110. Chow EJ, Chen Y, Hudson MM, Feijen EAM, Kremer LC, Border WL, Green DM, Meacham LR, Mulrooney DA, Ness KK, et al. Prediction of ischemic heart disease and stroke in survivors of childhood cancer. J Clin Oncol. 2018;36(1):44–52. https://doi.org/10.1200/JCO.2017.74.8673.

111. Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, version 5.0. Monrovia: Children’s Oncology Group; 2018. Available on-line: www.survivorshipsguidelines.org.

112. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, Li FP, Meadows AT, Mulvihill JJ, Neglia JP, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38(4):229–39. https://doi.org/10.1002/mpo.1316.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.